Flunisolide

Flunisolide is a corticosteroid, which is an orally active glucocorticoid receptor activator with anti-inflammatory activity. Flunisolide can induce eosinophil apoptosis, and is used for the research of asthma or rhinitis, and inflammation[1][2].

Product Specifications

CAS Number

[3385-03-3]

UNSPSC

12352005

Hazard Statement

H300

Target

Apoptosis; Glucocorticoid Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Endocrinology; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Flunisolide.html

Concentration

10mM

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@@]3(C(CO)=O)[C@@](OC(C)(O3)C)([H])C[C@@]1([H])[C@]4([H])C[C@H](F)C5=CC(C=C[C@]5(C)[C@@]4([H])[C@@H](O)C2)=O

Molecular Formula

C24H31FO6

Molecular Weight

434.50

Precautions

H300

References & Citations

[1]Tatiana Paula Teixeira Ferreira, et al. Intranasal Flunisolide Suppresses Pathological Alterations Caused by Silica Particles in the Lungs of Mice. Front Endocrinol (Lausanne) . 2020 Jun 17;11:388. |[2]M Profita, et al. In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics. Allergy. 2004 Sep;59 (9) :927-32. |[3]S Boero, et al. Modulation by flunisolide of tumor necrosis factor-alpha-induced stimulation of airway epithelial cell activities related to eosinophil inflammation. J Asthma. 2010 May;47 (4) :381-7. |[4]B I Florea, et al. Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3) . Br J Pharmacol. 2001 Dec;134 (7) :1555-63.